Losartan, an ARB, has shown promising pre-clinical results in the treatment of disuse atrophy and impaired regeneration in the context of sarcopenia through the modulation of the TGF-β and Akt/mTOR pathways [60]. This evidence concerns the gene TGFB1 and sarcopenia.